Friday July 10, 2020 15:35

Heathcare Press Release : 30 Jun 2020

RevImmune Announces Phase II Trial of the T-Cell Growth Factor CYT107 for Heathcare—30 Jun 20

RevImmune, a privately held biotechnology company developing CYT107 immune therapy for infectious diseases and cancer, announced today that it has launched the "ILIAD" Phase II trial for treatment of COVID-19. Many COVID-19 clinical trials have focused

MedAlliance Gains CE Mark Approval for Coronary SELUTION SLR(TM) Sirolimus Drug Eluting Heathcare—30 Jun 20

MedAlliance has announced the award of its second CE Mark: SELUTION SLR(TM) 014 PTCA, a novel Sirolimus Drug Eluting Balloon (DEB), for the treatment of coronary arterial disease. This includes indications for both de-novo lesions as well as in-stent